Showing 1111-1120 of 1148 results for "".
- Opicapone Decreases Off Time in Parkinson Diseasehttps://practicalneurology.com/news/opicapone-decreases-off-time-in-parkinson-disease/2469380/Post hoc analyses presented at the Movement Disorder Society's Virtual Congress 2020 September 12-16 showed once-daily opicapone (Ongentys; Neurocrine Biosciences, San Diego, CA) decreased off time’ and increased on time without troublesome dyskinesia in Parkinson disease (PD). Opicapon
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is
- FDA Grants Orphan Drug Designation for Primary Mitochondrial Myopathies Treatmenthttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-for-primary-mitochondrial-myopathies-treatment/2469310/The Food and Drug Administration (FDA) office of orphan products development has granted orphan drug designation to a peroxisome proliferator-activated receptor (PPAR) delta agonist, (REN001; Reneo Pharmaceuticals, San Diego, CA), for the treatment of primary mitochondrial myopathies (PMM).
- New Indication for Pimavanserin—Dementia Related Psychosis—Submitted to the FDAhttps://practicalneurology.com/news/new-indication-for-pimavanserin-dementia-related-psychosis-submitted-to-the-fda/2469301/A supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaseuticals, San Diego, CA) was submitted to the Food and Drug Administration (FDA) for a new indication. Evidence now shows pimavanserin is effective for the treatment of hallucinations and delusions associated wit
- Phase 2 Clinical Trial of LSD for Cluster Headaches Initiatedhttps://practicalneurology.com/news/phase-2-clinical-trial-of-lsd-for-cluster-headaches-initiated/2469288/A phase 2 trial (NCT03781128) for lysergic acid diethylamide (LSD) pulse regimen (Mind Medicine, Basel, Switzerland) for cluster headache treatment started recruiting participants in
- FDA Approves Opicapone as Adjunctive to Levodopa for Parkinson Diseasehttps://practicalneurology.com/news/fda-approves-opicapone-as-adjunctive-to-levodopa-for-parkinson-disease/2469240/The US Food and Drug Administration (FDA) has approved once-daily oral opicapone (Ongentys, Neurocrine Biosciences, San Diego, CA) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in individuals with Parkinson disease (PD) experiencing off episodes. Opicapone also increases o
- Diazepam Nasal Spray is Commercially Available for Seizure Treatmenthttps://practicalneurology.com/news/diazepam-nasal-spray-is-commercially-available-for-seizure-treatment/2469176/Diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) is now commercially available. The Food and Drug Administration (FDA) approved diazepam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in January 2020. "We understa
- FDA Approves Diazepam Nasal Spray For Acute Treatment of Seizure Clustershttps://practicalneurology.com/news/fda-approves-diazepam-nasal-spray-for-acute-treatment-of-seizure-clusters/2469129/The Food and Drug Administration (FDA) has approved a diazepam nasal spray (Valtoco; Neurelis, San Diego, CA) as an acute treatment of intermittent stereotypic episodes of frequent seizure activity. The treatment is indicated for seizure clusters and acute repetit
- Study Shows Obesity May be an Early Sign of Dementia And Not a Causehttps://practicalneurology.com/news/study-shows-obesity-may-be-an-early-sign-of-dementia-and-not-a-cause/2469115/A large study has found that obesity in midlife is linked to a greater risk of dementia later in life; however, poor diet and lack of exercise are not. The study is published in the December 18, 2019, online issue of
- First-In-Human Study Results Show PTI-125, An Investigational Agent, Reduces Biomarkers of Alzheimer’s Disease, Inflammation, and Neurodegenerationhttps://practicalneurology.com/news/first-in-human-study-results-show-pti-125-a-investigational-agent-reduces-biomarkers-of-alzheimers-disease-inflammation-and-neurodegeneration/2469106/At the Clinical Trials in Alzheimer Disease meeting in San Diego, CA December 4-7, 2019, results of an open label first-in-human clinical trial (NCT03748706) of PTI-125 (Cassava Sciences, Austin, TX) were presented. An investigati